Studies have also suggested that treatment targeting VEGF significantly attenuates bleomycin-induced pulmonary fibrosis in vivo (Hamada et al., 2005; Wan et al., 2013; Iyer et al., 2015; Laddha and Kulkarni, 2019). This evidence concerns the gene VEGFA and pulmonary fibrosis.